Recent stock performance and business snapshot

With no single headline event driving recent trading, Progyny (PGNY) has moved on a mix of short term gains and longer term volatility, giving investors fresh numbers to reassess the fertility benefits provider.

Over the past month, the stock gained about 33%, while the past 3 months show a rise of roughly 11%. In contrast, the year to date performance is down around 11%, and the 3 year and 5 year total returns are also negative.

Progyny operates as a benefits management company focused on fertility, family building, and women’s health solutions in the United States, reporting revenue of US$1.29b and net income of US$67.69m. The company’s value score is listed as 5, which some investors may use as one reference point when comparing it with other healthcare benefit stocks.

Progyny’s share price has recently moved higher, with a 7 day share price return of 19.36% and a 30 day share price return of 33.20%. However, longer term total shareholder returns remain mixed, with the 1 year total shareholder return at 4.19%, while the 3 year and 5 year total shareholder returns are still in decline.

If Progyny’s recent rebound has you thinking about where else momentum and fundamentals might align, it could be worth scanning for other healthcare focused opportunities through a curated list of 34 healthcare AI stocks

So with Progyny trading at US$22.87, carrying an intrinsic value estimate at a sizeable discount and sitting below some analyst targets, is the recent rally an entry point, or is the market already pricing in future growth?

Most Popular Narrative: 26% Undervalued

Progyny's most followed narrative pegs fair value at $30.91, well above the last close at $22.87. This puts a spotlight on the gap investors are being asked to weigh.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross-sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Curious what earnings, revenue mix, and future margin profile have to look like for this valuation to add up? The assumptions behind that gap are anything but simple.

Result: Fair Value of $30.91 (UNDERVALUED)

However, there are still clear watchpoints, including tighter employer benefit budgets and rising competition in fertility and women’s health, that could challenge this upside story.

Next Steps

With sentiment clearly split between upside potential and real risks, it makes sense to review the underlying data yourself and move quickly if you want conviction, starting with the 4 key rewards

Looking for more investment ideas?

If Progyny is on your radar, do not stop there. A few minutes with the right stock lists could surface opportunities that fit your style even better.

• Pinpoint resilient companies that aim to protect capital by filtering for 67 resilient stocks with low risk scores built around lower risk profiles and steadier fundamentals.
• Target strong businesses at potentially appealing prices by scanning a curated set of 48 high quality undervalued stocks that combine quality with compressed valuations.
• Spot lesser known opportunities early by working through a screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.